These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 39282119)
1. Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Xu Y; Xu Y; Yang Y; Zhang Z; Xiong Q; Zhu Q PeerJ; 2024; 12():e18018. PubMed ID: 39282119 [TBL] [Abstract][Full Text] [Related]
2. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698 [TBL] [Abstract][Full Text] [Related]
5. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167 [TBL] [Abstract][Full Text] [Related]
6. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603 [TBL] [Abstract][Full Text] [Related]
7. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy. Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876 [TBL] [Abstract][Full Text] [Related]
8. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157 [TBL] [Abstract][Full Text] [Related]
9. Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer. Wei Q; Zhang J; Li Z; Wei L; Ren L Pancreas; 2020 Oct; 49(9):1213-1219. PubMed ID: 32898008 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450 [TBL] [Abstract][Full Text] [Related]
11. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294 [TBL] [Abstract][Full Text] [Related]
12. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522 [TBL] [Abstract][Full Text] [Related]
13. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer. Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469 [TBL] [Abstract][Full Text] [Related]
14. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance. Jia F; Liu M; Li X; Zhang F; Yue S; Liu J World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392 [TBL] [Abstract][Full Text] [Related]
15. Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer. Pang L; Zhang N; Xia Y; Wang D; Wang G; Meng X Oncotarget; 2016 Nov; 7(47):77854-77864. PubMed ID: 27788483 [TBL] [Abstract][Full Text] [Related]
16. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937 [TBL] [Abstract][Full Text] [Related]
19. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219 [TBL] [Abstract][Full Text] [Related]
20. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Joergensen MT; Brünner N; De Muckadell OB Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]